ClinicalTrials.gg
CompletedNCT00732875Updated Apr 13, 2017Results posted

A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)

A Phase 3 interventional study of Infliximab + methotrexate (MTX) in Arthritis, Rheumatoid, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
92
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 49 studies testing infliximab in Arthritis, Rheumatoid — 2 open to participants now, 3 under way, 1 of them phase 3. Infliximab · Arthritis, Rheumatoid.

Enrollment
34th of 49
92 · median 172
Started
2006
with 1 other
Phase 3
19 of 49
1 open now
Registered
16th of 49
by date
Lead sponsor
5 of 49
Merck Sharp & Dohme LLC

Among the 49 studies testing infliximab in Arthritis, Rheumatoid, this one is the 34th largest by enrollment, is one of 2 that started in 2006, is one of 19 in phase 3, and was the 16th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 49 studies testing infliximab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing infliximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This trial is extension part of the P04280 (placebo-controlled, double-blind, randomized study of chronic treatment with infliximab in approximately 140 patients, NCT00202852). This study will be conducted at 6 study centers in South Korea. After completion of the last follow-up visit at Week 30 and code break in main double-blind trial, subjects randomized to the placebo group and those who were treated with an infliximab-containing regimen who maintained clinical response at the time of study completion will be provided with open-label infliximab for treatment of their conditions and additional safety data will be collected.

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients received placebo in main double-blind study (P04280, NCT00202852)
  • Patients received Infliximab-containing regimen showing clinical response at week 30 in main double-blind study (P04280)

[Main double-blind study (P04280, NCT00202852) inclusion criteria]

  • Diagnosis of rheumatoid arthritis (RA) according to the revised 1987 criteria of the American Rheumatism Association (Arnett et al, 1988). The disease should have been diagnosed >6 months prior to screening.
  • Active disease at the time of screening and pre-infusion as defined by:

    • >=6 swollen joints
    • >=6 tender joints and
  • 2 of the following:

    • morning stiffness >=45 min
    • erythrocyte sedimentation rate (ESR) >=28 mm/h
    • C-reactive protein (CRP) >=20 mg/L
  • Men and women, >=18 to \<=75 years of age
  • Men and women of must be using adequate measures (abstinence, oral contraceptives, intrauterine device (IUD), barrier method with spermicide, or surgical sterilization) and should continue such precautions for 6 months after receiving the last infusion.
  • Must have been using oral or parenteral MTX for >3 months with no break(s) in treatment of >2 weeks total during this period. Patients must have been on a stable dose of >=12.5 mg/wk (maximum 20 mg/wk) for at >4 weeks prior to screening.
  • Must be on a stable dose of folic acid prophylaxis for >4 weeks prior to screening.
  • Patients using oral , must have been on a stable dose of \<=10 mg/day for >4 weeks prior to screening. If currently not using corticosteroids the patient must have not received corticosteroids for >4 weeks prior to screening.
  • If using nonsteroidal anti-inflammatory drugs (NSAIDs), patients should have been on a stable dose for >4 weeks prior to screening.
  • The screening laboratory tests must meet the following criteria:

    • >=5.3 mmol/L (>=8.5 g/dL), providing a low hemoglobin level is not due to nutritional deficiencies or due to diseases other than chronic RA
    • white blood cell (WBC) >=3.5 x 10\^9/L (>=3.5 x 10\^3/mm\^3)
    • Neutrophils >=1.5 x 10\^9/L (>=1.5 x 103/mm\^3)
    • >=100 x 10\^9/L (>=100 x 103/mm\^3)
    • Serum transaminase \<=2 times the
    • Alkaline phosphatase levels \<=2 times the upper limit of normal
    • Serum creatinine \<=150 µmol/L (\<=1.7 mg/dL)
  • Must be able to adhere to the study visit schedule and other protocol requirements.
  • Must be capable of giving and the consent must have been obtained prior to any study procedures including .

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria below of main double-blind study (P04280, NCT00202852)

[Main double-blind study (P04280, NCT00202852) exclusion criteria]

  • Pregnant women, nursing mothers, or a planned pregnancy within 1.5 years of enrollment.
  • Patients who are incapacitated, largely or wholly bedridden or confined to a wheelchair, and who have little or no ability for self-care.
  • Patients who have any current systemic inflammatory condition with signs and symptoms that might confound the evaluations of benefit from infliximab, eg Lyme disease, or a rheumatic disease other than RA.
  • Use of disease modifying anti-rheumatic drugs (DMARDs) other than MTX within 4 weeks prior to screening. (If a patient had prior exposure to leflunomide within the past 6 months, cholestyramine 8 g should be given 3 times daily for 11 days to rapidly lower the plasma level of leflunomide.)
  • Use of intra-articular, i.m. or i.v. (including i.m. ACTH) within 4 weeks prior to screening.
  • Have been previously treated with infliximab or genetic recombinant therapy with RA (e.g. etanercept, adalimumab)
  • Treatment with any other therapeutic agent targeted at reducing TNF (eg, pentoxifylline or thalidomide) within the previous 3 months.
  • Treatment with any drug within the previous 3 months.
  • Prior use of cyclophosphamide, nitrogen mustard, chlorambucil, or other alkylating agents.
  • History of any adverse reaction to murine or chimeric proteins, including but not limited to allergic reactions.
  • History of infected joint prosthesis within previous 5 years.
  • Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3 months.
  • Chronic infectious disease such as chronic renal infection, chronic chest infection with bronchiectasis or sinusitis.
  • Active tuberculosis (TB). Also excluded are patients who have evidence of latent TB (positive purified protein derivative [PPD] skin test or a history of latent TB) without adequate therapy for TB initiated prior to first infusion of study drug. Also excluded are patients with evidence of an old or latent TB infection without documented adequate therapy, if they will not be treated with antitubercular therapy during the trial. Patients with a current close contact with an individual with active TB will also be excluded. Additionally, patients who have completed treatment for active TB within the previous 2 years are now explicitly excluded from the trial. Patients with a household member who has a history of active pulmonary TB should have had a thorough evaluation for TB prior to study enrollment as recommended by a local infectious disease specialist or published local guidelines of TB control agencies. Also excluded are patients with opportunistic infections, including but not limited to evidence of active cytomegalovirus, active Pneumocystis carinii, aspergillosis, or atypical mycobacterial infection, etc, within the previous 6 months.
  • Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral disease.
  • History of lymphoproliferative disease including lymphoma or signs suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic areas), or splenomegaly.
  • Any current known or history of malignancy within the previous 5 years, except for squamous or basal cell carcinoma of the skin that have been treated with no evidence of recurrence.
  • Patients with moderate or severe heart failure ( [NYHA] class III/IV).
  • Patients with pre-existing or recent onset of central nervous system demyelinating disorders.
  • Known recent substance abuse (drug or alcohol).
  • Patients in whom multiple venipunctures are not feasible due to poor tolerability or lack of easy access.
  • Have a known infection with or known active /C infection (including associated chronic active hepatitis).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Open Label Infliximab + Methotrexate

    Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)

    Biological: Infliximab + methotrexate (MTX)

Interventions

  • BiologicalInfliximab + methotrexate (MTX)

    Drug pages: Infliximab · Methotrexate

    Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)

    Also known as: Remicade, SCH 215596

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experiencing Any Adverse Event

    Time frame: throughout entire study (61 +/- 28.9 weeks on average)

  2. Number of Subjects Experiencing Serious Adverse Event

    Serious adverse events are defined as death, life-threatening events, persistent or significant disability/incapacity, hospitalization or prolongation of hospitalization and congenital anomalies.

    Time frame: throughout entire study (61 +/- 28.9 weeks on average)

  3. Number of Subjects Experiencing Any Infection

    Time frame: throughout entire study (61 +/- 28.9 weeks on average)

07

Results

Posted Jul 21, 2009

Participant flow

Subjects showing clinical response at Week 30 of a previous double-blind study of infliximab vs placebo (P04280,NCT00202852) were eligible for this study. A total of 105 subjects were eligible (67 from previous placebo \& 38 from previous infliximab group) for this extension study, among whom a total of 92 enrolled to participate in the extension.

Participant flow — Overall Study
MilestoneOpen Label Infliximab + Methotrexate
Started92
Completed57
Not completed35
Withdrew: Adverse event16
Withdrew: Withdrawal by subject6
Withdrew: Lack of efficacy13

Outcome measures

PrimaryNumber of Subjects Experiencing Any Adverse Event
Time frame:
throughout entire study (61 +/- 28.9 weeks on average)
Reported as:
Number · participants
Number of Subjects Experiencing Any Adverse Event
participantsOpen Label Infliximab + Methotrexate
Number of Subjects Experiencing Any Adverse Event76
PrimaryNumber of Subjects Experiencing Serious Adverse Event

Serious adverse events are defined as death, life-threatening events, persistent or significant disability/incapacity, hospitalization or prolongation of hospitalization and congenital anomalies.

Time frame:
throughout entire study (61 +/- 28.9 weeks on average)
Reported as:
Number · participants
Number of Subjects Experiencing Serious Adverse Event
participantsOpen Label Infliximab + Methotrexate
Number of Subjects Experiencing Serious Adverse Event12
PrimaryNumber of Subjects Experiencing Any Infection
Time frame:
throughout entire study (61 +/- 28.9 weeks on average)
Reported as:
Number · participants
Number of Subjects Experiencing Any Infection
participantsOpen Label Infliximab + Methotrexate
Number of Subjects Experiencing Any Infection41

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label Infliximab + Methotrexate—12/92 (13%)50/92 (54.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventOpen Label Infliximab + Methotrexate
chronic sinusitisInfections and infestations2/92
arthralgiaMusculoskeletal and connective tissue disorders2/92
urticariaSkin and subcutaneous tissue disorders2/92
AnaemiaBlood and lymphatic system disorders1/92
gastric ulcerGastrointestinal disorders1/92
chest discomfortGeneral disorders1/92
inflammationGeneral disorders1/92
infusion related reactionGeneral disorders1/92
ulcerGeneral disorders1/92
cholecystitis acuteHepatobiliary disorders1/92
Most frequent other events
Showing 10 of 13
Most frequent other events
EventOpen Label Infliximab + Methotrexate
upper respiratory tract infectionInfections and infestations19/92
pruritusSkin and subcutaneous tissue disorders11/92
urticariaSkin and subcutaneous tissue disorders9/92
nauseaGastrointestinal disorders8/92
headacheNervous system disorders8/92
chillsGeneral disorders6/92
nasopharyngitisInfections and infestations6/92
alanine aminotransferase increasedInvestigations6/92
coughRespiratory, thoracic and mediastinal disorders6/92
diarrhoeaGastrointestinal disorders5/92

Baseline characteristics

Age, Continuous
Age, Continuous(years)Open Label Infliximab + Methotrexate
Mean50.1 ± 11.1
Age, Customized
Age, Customized(participants)Open Label Infliximab + Methotrexate
<30 years2
Between 30 and less than 40 years14
Between 40 and less than 50 years29
Between 50 and less than 60 years29
Between 60 and less than 70 years15
>=70 years3
Sex: Female, Male
Sex: Female, Male(Participants)Open Label Infliximab + Methotrexate
Female86
Male6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kim J, Ryu H, Yoo DH, Park SH, Song GG, Park W, Cho CS, Song YW. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. J Korean Med Sci. 2013 Dec;28(12):1716-22. doi: 10.3346/jkms.2013.28.12.1716. Epub 2013 Nov 26. PubMed 24339699 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2008
First posted
Aug 12, 2008
Start
Aug 2006
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Jul 21, 2009
Last update
Apr 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00732875
Responsible party
Sponsor
First posted
Aug 12, 2008
Start date
Aug 2006
Primary completion
May 2008
Completion
May 2008
Results posted
Jul 21, 2009
Last update
Apr 13, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Infliximab · Methotrexate

Start the discussion